Evercore ISI initiated coverage of Repligen (RGEN) with an In Line rating and $155 price target The firm sees the company as a high quality pure play bioprocess supplier with $649M of revenue and a market cap of about $8B, the analyst tells investors in a research note. After two consecutive years of organic declines, Repligen looks positioned to benefit from market recovery and continue to grow more than 500-1000 bps above market growth rate amid outperformance driven by differentiated products and higher clinical mix, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN:
- Repligen’s Strategic Acquisition of 908 Devices’ Assets: A Buy Rating for Long-term Shareholder Value
- Repligen’s Strategic Acquisition: Hold Rating Amid Short-term Financial Dilution and Long-term Growth Potential
- Repligen deal can expand bioprocessing opportunities, says RBC Capital
- Repligen’s Strategic Acquisition of 908 Devices’ Bioprocessing Assets Boosts Buy Rating
- Repligen acquires bioprocessing analytic portfolio from 908 Devices for $70M